Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients

被引:43
作者
Han, Fei-fei [1 ]
Guo, Chang-long [2 ,3 ]
Yu, Dan [4 ]
Zhu, Jin [1 ]
Gong, Li-li [1 ]
Li, Guang-run [1 ]
Lv, Ya-li [1 ]
Liu, He [1 ]
An, Guang-yu [4 ]
Liu, Li-hong [1 ]
机构
[1] Capital Med Univ, Beijing ChaoYang Hosp, Dept Pharm, Beijing 100020, Peoples R China
[2] Natl Res Inst Family Planning, Reprod & Genet Ctr, Beijing 100081, Peoples R China
[3] Peking Union Med Coll, Grad Sch, Beijing 100730, Peoples R China
[4] Capital Med Univ, Beijing ChaoYang Hosp,Capital, Dept Oncol, Beijing 100020, Peoples R China
关键词
UGT1A1*6; UGT1A1*6/*28; Neutropenia; Irinotecan; Asian cancer population; UDP-GLUCURONOSYLTRANSFERASE; 1A1-ASTERISK-6; PHASE-II TRIAL; COMBINATION CHEMOTHERAPY; COMPREHENSIVE ANALYSIS; GENETIC-VARIANTS; UGT1A1; TOXICITY; JAPANESE; TRANSFERASE; GENOTYPE;
D O I
10.1007/s00280-014-2405-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Neutropenia is a life-threatening side effect of irinotecan, and uridine diphosphate glucuronosyltransferases(UGTs) gene polymorphisms are considered to be one of the predictive markers of irinotecan-related toxicities. Many studies have demonstrated that patients bearing UGT1A1*28 have a higher risk of severe neutropenia on toxicity of irinotecan. However, UGT1A1 (TA7/TA7) was very rare in Asian populations. Some researches reported that UGT1A1*28 and/or UGT1A1*6 could predict irinotecan-induced toxicities in Asian populations, but controversial conclusions still remained. This study aims to investigate the association between UGT1A1 gene polymorphisms *6, *6/*28 and irinotecan-related neutropenia in Asian cancer patients receiving irinotecan regimen chemotherapy. Experimental design Meta-analyses were done to assess the relationship between UGT1A1*6 or UGT1A1*6/*28 and irinotecan-induced neutropenia. Results T he risk of neutropenia was significantly higher among patients with a UGT1A1*6 genotype than among those carrying the UGT1A1*1 allele(s) [odds ratio (OR) 3.276; 95 % confidence interval (CI) 1.887-5.688; P = 0.000 (*6/*6 vs. *1/*6 or *1/*1)], [OR 1.542; 95 % CI 1.180-2.041; P = 0.001 (*6/*6 or *1/*6 vs. *1/*1)]. Also, the risk was significantly higher among patients with a UGT1A1*6/*28 than among those carrying the UGT1A1*1 allele(s) [OR 3.275; 95 % CI 2.152-4.983; P = 0.000 (*6/*6 or *28/*28 or *6/*28 vs. *1/*6 or *1/*28 or *1/*1)]. Conclusions In conclusion, the UGT1A1*6 and UGT1A1*6/*28 genotypes were associated with an increased risk of irinotecan-induced neutropenia in Asian cancer patients.
引用
收藏
页码:779 / 788
页数:10
相关论文
共 42 条
[1]  
Ando Y, 2000, CANCER RES, V60, P6921
[2]   A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity [J].
Choi, Yoon Hee ;
Kim, Tae Won ;
Kim, Kyu-Pyo ;
Lee, Sung Sook ;
Hong, Yong Sang ;
Ryu, Min-Hee ;
Lee, Jae-Lyun ;
Chang, Heung Moon ;
Ryoo, Baek-Yeol ;
Kim, Ho-Sook ;
Shin, Jae-Gook ;
Kang, Yoon-Koo .
ONCOLOGY, 2012, 82 (05) :290-297
[3]   Pharmacogenomics: road to anticancer therapeutics nirvana? [J].
Desai, AA ;
Innocenti, F ;
Ratain, MJ .
ONCOGENE, 2003, 22 (42) :6621-6628
[4]   Bias in meta-analysis detected by a simple, graphical test [J].
Egger, M ;
Smith, GD ;
Schneider, M ;
Minder, C .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634
[5]   UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan [J].
Ferraldeschi, Robert ;
Minchell, Laura J. ;
Roberts, Stephen A. ;
Tobi, Simon ;
Hadfield, Kristen D. ;
Blackhall, Fiona H. ;
Mullamitha, Saifee ;
Wilson, Gregory ;
Valle, Juan ;
Saunders, Mark ;
Newman, William G. .
PHARMACOGENOMICS, 2009, 10 (05) :733-739
[6]   Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients [J].
Gao, Jing ;
Zhou, Jun ;
Li, Yanyan ;
Peng, Zhi ;
Li, Yilin ;
Wang, Xicheng ;
Shen, Lin .
MEDICAL ONCOLOGY, 2013, 30 (03)
[7]   UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients [J].
Gao, Jing ;
Zhou, Jun ;
Li, Yanyan ;
Lu, Ming ;
Jia, Ru ;
Shen, Lin .
MEDICAL ONCOLOGY, 2013, 30 (03)
[8]   Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer [J].
Glimelius, B. ;
Garmo, H. ;
Berglund, A. ;
Fredriksson, L. A. ;
Berglund, M. ;
Kohnke, H. ;
Bystrom, P. ;
Sorbye, H. ;
Wadelius, M. .
PHARMACOGENOMICS JOURNAL, 2011, 11 (01) :61-71
[9]   Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer [J].
Han, Ji-Youn ;
Lim, Hyeong-Seok ;
Park, Yong Hoon ;
Lee, Sung Young ;
Lee, Jin Soo .
LUNG CANCER, 2009, 63 (01) :115-120
[10]   Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin [J].
Han, Ji-Youn ;
Lim, Hyeong-Seok ;
Shin, Eun Soon ;
Yoo, Yeon-Kyeong ;
Park, Yong Hoon ;
Lee, Jong-Eun ;
Jang, In-Jin ;
Lee, Doe Ho ;
Lee, Jin Soo .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2237-2244